* Elevation Oncology Inc ELEV.OQ reported a quarterly
adjusted
loss of 18 cents per share for the quarter ended in June,
higher than the same quarter last year, when the company
reported EPS of -37 cents. The mean expectation of
seven analysts for the quarter was for a loss of 22 cents per
share. Wall Street expected results to range from -27 cents
to -19 cents per share.
* Reported revenue was zero; analysts expected zero.
* Elevation Oncology Inc's reported EPS for the quarter was
a loss
of 18 cents.
* The company reported a quarterly loss of $10.46 million.
* Elevation Oncology Inc shares had fallen by 21.1% this
quarter and gained 296.6% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 3% in
the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Elevation
Oncology Inc is $8.00
This summary was machine generated from LSEG data August 6 at
01:30 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.22 -0.18 Beat
Mar. 31 2024 -0.20 -0.23 Missed
Dec. 31 2023 -0.24 -0.19 Beat
Sep. 30 2023 -0.32 -0.25 Beat